Search | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. A Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s Choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

    ... with the exception that growth factors (G-CSF, erythropoietin , and TPO) and transfusions are allowed before and during the ...

    Clinical Trial last updated 05/04/2018 - 3:53pm.

  2. A Biomarker-Directed Phase 2 Trial of SY-1425, a Selective Retinoic Acid Receptor Alpha Agonist, in Adult Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

    ... the del 5q abnormality, in patients refractory to erythropoietin treatment or unlikely to respond to erythropoietin treatment (EPO >500). Lower-risk MDS: Very Low / Low / ...

    Clinical Trial last updated 04/23/2018 - 1:35pm.

  3. Erythropoietin inhibits osteoblast function in myelodysplastic syndromes via the canonical Wnt pathway

    ... The effects of erythropoietin on osteoblasts and bone formation are controversially ... myelodysplastic syndromes often display excessively high erythropoietin level, we aimed to analyze the effect of erythropoietin on ...

    Research Article last updated 11/08/2017 - 8:52am.

  4. Increasing the effectiveness of hematopoiesis in myelodysplastic syndromes: erythropoiesis-stimulating agents and transforming growth factor-β superfamily inhibitors

    ... erythropoiesis-stimulating agents (ESAs) such as erythropoietin (EPO) and mimetics are applied as first-line therapy in a ...

    Research Article last updated 10/23/2017 - 11:08am.

  5. Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond

    ... restores effective erythropoiesis via enhancement of erythropoietin (EPO) receptor-initiated transcriptional response arising ...

    Research Article last updated 10/23/2017 - 10:58am.

  6. Pro-inflammatory proteins S100A9 and TNFα suppress erythropoietin elaboration in myelodysplastic syndromes

    Journal Title:  Haematologica Primary Author:  Cluzeau T Author(s):  Cluzeau ...

    Research Article last updated 10/20/2017 - 9:16am.

  7. Foundation Update - April 2016

    ... as relatively low risk. I have been treated with erythropoietin (Procrit®), G-CSF, (Neupogen®), azacitidine , ...

    Article last updated 10/09/2017 - 2:57pm.

  8. Increasing the effectiveness of hematopoiesis in myelodysplastic syndromes: erythropoiesis-stimulating agents and transforming growth factor-β superfamily inhibitors

    ... erythropoiesis-stimulating agents (ESAs) such as erythropoietin (EPO) and mimetics are applied as first-line therapy in a ...

    Research Article last updated 10/02/2017 - 10:10am.

  9. Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond

    ... restores effective erythropoiesis via enhancement of erythropoietin (EPO) receptor-initiated transcriptional response arising ...

    Research Article last updated 10/02/2017 - 9:54am.

  10. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study

    ... vs <4 red blood cell units per 8 weeks); pre-study serum erythropoietin concentration (<200 IU/L, 200-500 IU/L, and >500 IU/L); ...

    Research Article last updated 09/18/2017 - 1:38pm.